FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886619454> ?p ?o ?g. }

• W2886619454 abstract "Renal Cell Carcinoma (RCC) contributes >90% of the most common form of kidney tumor and remains one of the ten leading causes of cancer death in the US. Tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have increased therapeutic possibilities for treating RCC. Although the impact on disease progression is encouraging, a substantial proportion of patients do not respond adequately, and therapy resistance almost inevitably occurs. Eventually, new strategies have emerged that include immunotherapy such as PD-1 inhibitor (Nivolumab) and the combination of chemo-immune therapy. Possibly, combination treatment aimed at different, non-related pathways may be advantageous. In this regard, we would like to come up with synergistic therapeutic strategies for nonresponsive, highly aggressive tumor types to tackle the current clinical challenges. We have worked on different RCCs tumor models that in general have a poor prognosis with conventional therapies. We also pursued different combination regimens, including drugs that work on the mTOR inhibition (everolimus), inhibit RTK-inhibitor or VEGFR (cabozantinib or sorafenib). Also, there is a critical need to develop safe and effective delivery vehicles that can carry the payload to the right target tissue and cell. Thus, different types of nanoparticles have been designed to deliver a variety of therapeutic agents to target hypoxic tumor microenvironment by using carbonic anhydrase-9 (CA9); FRα for targeting cancer epithelial cells; and FRβ for targeting tumor-associated macrophages (TAM) and combination delivery of RTK-inhibitor Cabozantinib (CB) and sorafenib with our own apoptosis inducer/CARP-1 protein activator CFM-4.16 (C4.16) for overcoming drug resistance and reprograming TAM for RCC therapy. The current work also focused on multimodal approaches, including (a) Optimization of hypoxia marker conjugated targeted polymer-lipid nano-formulation (PLNP) using copper-free click chemistry; (b) In vitro and in vivo pre-clinical testing of targeted -PLNP loaded with polypharmacy in inhibiting RCCs using mice bearing resistant RCCs and patient-derived xenografts (PDX). The results of efficacy and biodistribution of targeted PLNPs in animals bearing RCC xenografts and PDX model showed higher accumulation of drugs at tumor sites with higher tumor growth inhibition. Also, the targeted formulation showed high binding affinity and specific tumor uptake, faster normal tissue clearance, and less non-target organ uptake. These findings portent promising therapeutic potential of hypoxia-targeted -PLNPs for treating RCCs. Citation Format: Hashem O. Alsaab, Samaresh Sau, Vino T. Cheriyan, Rami Alzhrani, Ulka Vaishampayan, Arun K. Rishi, Arun K. Iyer. Tumor multicomponent targeting nano-micelles with synergistic combination to overcome drug resistance and reprogramming of macrophages in renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3716." @default.
• W2886619454 created "2018-08-22" @default.
• W2886619454 creator A5018818727 @default.
• W2886619454 creator A5045993993 @default.
• W2886619454 creator A5046061905 @default.
• W2886619454 creator A5048696566 @default.
• W2886619454 creator A5073593424 @default.
• W2886619454 creator A5086917113 @default.
• W2886619454 creator A5091506580 @default.
• W2886619454 date "2018-07-01" @default.
• W2886619454 modified "2023-09-27" @default.
• W2886619454 title "Abstract 3716: Tumor multicomponent targeting nano-micelles with synergistic combination to overcome drug resistance and reprogramming of macrophages in renal cell carcinoma" @default.
• W2886619454 doi "https://doi.org/10.1158/1538-7445.am2018-3716" @default.
• W2886619454 hasPublicationYear "2018" @default.
• W2886619454 type Work @default.
• W2886619454 sameAs 2886619454 @default.
• W2886619454 citedByCount "0" @default.
• W2886619454 crossrefType "proceedings-article" @default.
• W2886619454 hasAuthorship W2886619454A5018818727 @default.
• W2886619454 hasAuthorship W2886619454A5045993993 @default.
• W2886619454 hasAuthorship W2886619454A5046061905 @default.
• W2886619454 hasAuthorship W2886619454A5048696566 @default.
• W2886619454 hasAuthorship W2886619454A5073593424 @default.
• W2886619454 hasAuthorship W2886619454A5086917113 @default.
• W2886619454 hasAuthorship W2886619454A5091506580 @default.
• W2886619454 hasConcept C121608353 @default.
• W2886619454 hasConcept C126322002 @default.
• W2886619454 hasConcept C183713625 @default.
• W2886619454 hasConcept C190283241 @default.
• W2886619454 hasConcept C2776107976 @default.
• W2886619454 hasConcept C2776820818 @default.
• W2886619454 hasConcept C2776999253 @default.
• W2886619454 hasConcept C2777472916 @default.
• W2886619454 hasConcept C2777701055 @default.
• W2886619454 hasConcept C2778019345 @default.
• W2886619454 hasConcept C2778695046 @default.
• W2886619454 hasConcept C2779699572 @default.
• W2886619454 hasConcept C2781064419 @default.
• W2886619454 hasConcept C2781230642 @default.
• W2886619454 hasConcept C502942594 @default.
• W2886619454 hasConcept C55493867 @default.
• W2886619454 hasConcept C71924100 @default.
• W2886619454 hasConcept C86554907 @default.
• W2886619454 hasConcept C86803240 @default.
• W2886619454 hasConcept C96232424 @default.
• W2886619454 hasConcept C98274493 @default.
• W2886619454 hasConceptScore W2886619454C121608353 @default.
• W2886619454 hasConceptScore W2886619454C126322002 @default.
• W2886619454 hasConceptScore W2886619454C183713625 @default.
• W2886619454 hasConceptScore W2886619454C190283241 @default.
• W2886619454 hasConceptScore W2886619454C2776107976 @default.
• W2886619454 hasConceptScore W2886619454C2776820818 @default.
• W2886619454 hasConceptScore W2886619454C2776999253 @default.
• W2886619454 hasConceptScore W2886619454C2777472916 @default.
• W2886619454 hasConceptScore W2886619454C2777701055 @default.
• W2886619454 hasConceptScore W2886619454C2778019345 @default.
• W2886619454 hasConceptScore W2886619454C2778695046 @default.
• W2886619454 hasConceptScore W2886619454C2779699572 @default.
• W2886619454 hasConceptScore W2886619454C2781064419 @default.
• W2886619454 hasConceptScore W2886619454C2781230642 @default.
• W2886619454 hasConceptScore W2886619454C502942594 @default.
• W2886619454 hasConceptScore W2886619454C55493867 @default.
• W2886619454 hasConceptScore W2886619454C71924100 @default.
• W2886619454 hasConceptScore W2886619454C86554907 @default.
• W2886619454 hasConceptScore W2886619454C86803240 @default.
• W2886619454 hasConceptScore W2886619454C96232424 @default.
• W2886619454 hasConceptScore W2886619454C98274493 @default.
• W2886619454 hasLocation W28866194541 @default.
• W2886619454 hasOpenAccess W2886619454 @default.
• W2886619454 hasPrimaryLocation W28866194541 @default.
• W2886619454 hasRelatedWork W1160931957 @default.
• W2886619454 hasRelatedWork W1938559619 @default.
• W2886619454 hasRelatedWork W1984445079 @default.
• W2886619454 hasRelatedWork W2124138175 @default.
• W2886619454 hasRelatedWork W2137381953 @default.
• W2886619454 hasRelatedWork W2763113537 @default.
• W2886619454 hasRelatedWork W2772286407 @default.
• W2886619454 hasRelatedWork W2799699422 @default.
• W2886619454 hasRelatedWork W2886619454 @default.
• W2886619454 hasRelatedWork W4211088407 @default.
• W2886619454 isParatext "false" @default.
• W2886619454 isRetracted "false" @default.
• W2886619454 magId "2886619454" @default.
• W2886619454 workType "article" @default.